邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新型冠状病毒肺炎合并肥胖症的评估与治疗策略

王诗蕊,  陈适,  朱惠娟

downloadPDF
文章导航 > 协和医学杂志  > 2021 >  12(1): 13-17
王诗蕊, 陈适, 朱惠娟. 新型冠状病毒肺炎合并肥胖症的评估与治疗策略[J]. 协和医学杂志, 2021, 12(1): 13-17. doi: 10.12290/xhyxzz.20200244
引用本文: 王诗蕊, 陈适, 朱惠娟. 新型冠状病毒肺炎合并肥胖症的评估与治疗策略[J]. 协和医学杂志, 2021, 12(1): 13-17. doi: 10.12290/xhyxzz.20200244
shu
WANG Shi-rui, CHEN Shi, ZHU Hui-juan. Evaluation and Treatment of Coronavirus Disease 2019 with Obesity[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 13-17. doi: 10.12290/xhyxzz.20200244
Citation: WANG Shi-rui, CHEN Shi, ZHU Hui-juan. Evaluation and Treatment of Coronavirus Disease 2019 with Obesity[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 13-17. doi: 10.12290/xhyxzz.20200244
shu

新型冠状病毒肺炎合并肥胖症的评估与治疗策略

doi: 10.12290/xhyxzz.20200244
  • 1.

    中国医学科学院 北京协和医学院临床医学八年制，北京 100730

  • 2.

    中国医学科学院 北京协和医学院 北京协和医院内分泌科 国家卫健委内分泌重点实验室，北京 100730

基金项目: 

中国医学科学院医学与健康科技创新工程 2016-I2M-1-002

详细信息
    通讯作者:

    ZHU Hui-juan  Tel: 86-10-69155845，E-mail：shengxin2004@163.com

  • 中图分类号: R511;R589;R18

Evaluation and Treatment of Coronavirus Disease 2019 with Obesity

  • 1.

    Eight-year Program of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

CAMS Innovation Fund for Medical Sciences 2016-I2M-1-002

    摘要
  • 摘要: 新型冠状病毒肺炎(coronavirus disease 2019，COVID-19)已成为危及全球的传染性疾病，重症患者死亡风险极高。临床研究显示，肥胖症是COVID-19患者发生重症及死亡的独立危险因素。对于合并肥胖症的COVID-19患者，应尽早评估肥胖相关合并症，并在营养、气道管理、抗凝、合并症控制等方面采取更积极的干预措施，以改善预后。
    Abstract: The pandemic of coronavirus disease 2019 (COVID-19) has spread worldwide and the mortality is high in severe COVID-19 patients. Clinical studies suggested that obesity is an independent risk factor for severe and dead cases of COVID-19. For COVID-19 patients with obesity, early evaluation of obesity-related comorbidities and aggressive treatments, including diet control, airway management, anticoagulant thromboprophylaxis, and management of comorbidities, are encouraged to improve their prognosis.
    作者贡献：王诗蕊负责资料收集、论文撰写；陈适、朱慧娟负责选题构思、论文修订。
    利益冲突  无
    • HTML全文
    • 参考文献(43)
  • [1] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med, 2020, 382:1708-1720. doi:  10.1056/NEJMoa2002032
    [2] Global Health Obsevatory (GHO) data: overweight and obesity [EB/OL]. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
    [3] Huang Y, Lu Y, Huang YM, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis[J]. Metabolism, 2020, 113: 154378. doi:  10.1016/j.metabol.2020.154378
    [4] Hussain A, Mahawar K, Xia Z, et al. Obesity and mortality of COVID-19. Meta-analysis[J]. Obes Res Clin Pract, 2020, 14: 295-300. doi:  10.1016/j.orcp.2020.07.002
    [5] Du Y, Lv Y, Zha W, et al. Association of Body mass index (BMI) with Critical COVID-19 and in-hospital Mortality: a dose-response meta-analysis[J]. Metabolism, 2020. doi: 10.1016/j.metabol.2020.154373: 154373.
    [6] Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China[J]. Diabetes Care, 2020, 43: 1392-1398. doi:  10.2337/dc20-0576
    [7] Soeroto AY, Soetedjo NN, Purwiga A, et al. Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis[J]. Diabetes Metab Syndr, 2020, 14: 1897-1904. doi:  10.1016/j.dsx.2020.09.029
    [8] Földi M, Farkas N, Kiss S, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis[J]. Obes Rev, 2020, 21:e13095.
    [9] Seidu S, Gillies C, Zaccardi F, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis[J]. Endocrinol Diabetes Metab, 2020. doi: 10.1002/edm2.176: e00176.
    [10] Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms[J]. Circulation, 2020, 142: 4-6. doi:  10.1161/CIRCULATIONAHA.120.047659
    [11] Nakeshbandi M, Maini R, Daniel P, et al. The impact of obesity on COVID-19 complications: a retrospective cohort study[J]. Int J Obes (Lond), 2020, 44: 1832-1837. doi:  10.1038/s41366-020-0648-x
    [12] Tsuriya D, Morita H, Morioka T, et al. Significant correla-tion between visceral adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects[J]. Intern Med, 2011, 50: 2767-2773. doi:  10.2169/internalmedicine.50.5908
    [13] Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis[J]. J Community Health, 2020, 45: 1270-1282. doi:  10.1007/s10900-020-00920-x
    [14] Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults[J]. Biomed Environ Sci, 2004, 17 Suppl: 1-36. doi:  10.1111/j.1365-2028.2008.00991.x
    [15] Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update[J]. Physiol Rev, 2013, 93: 359-404. doi:  10.1152/physrev.00033.2011
    [16] Sharma AM, Kushner RF. A proposed clinical staging system for obesity[J]. Int J Obes (Lond), 2009, 33: 289-295. doi:  10.1038/ijo.2009.2
    [17] Petersen A, Bressem K, Albrecht J, et al. The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany[J]. Metabolism, 2020, 110: 154317. doi:  10.1016/j.metabol.2020.154317
    [18] Chiappetta S, Sharma AM, Bottino V, et al. COVID-19 and the role of chronic inflammation in patients with obesity[J]. Int J Obes (Lond), 2020, 44: 1790-1792. doi:  10.1038/s41366-020-0597-4
    [19] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19[J]. J Infect, 2020, 80: 607-613. doi:  10.1016/j.jinf.2020.03.037
    [20] Watanabe M, Caruso D, Tuccinardi D, et al. Visceral fat shows the strongest association with the need of intensive Care in Patients with COVID-19[J]. Metabolism, 2020, 111:154319. doi:  10.1016/j.metabol.2020.154319
    [21] Yang Y, Ding L, Zou X, et al. Visceral Adiposity and High Intramuscular Fat Deposition Independently Predict Critical Illness in Patients with SARS-CoV-2[J]. Obesity (Silver Spring), 2020, 28: 2040-2048. doi:  10.1002/oby.22971
    [22] Dixon AE, Peters U. The effect of obesity on lung function[J]. Expert Rev Respir Med, 2018, 12: 755-767. doi:  10.1080/17476348.2018.1506331
    [23] Memtsoudis SG, Ivascu NS, Pryor KO, et al. Obesity as a risk factor for poor outcome in COVID-19-induced lung injury: the potential role of undiagnosed obstructive sleep apnoea[J]. Br J Anaesth, 2020, 125: e262-e263. doi:  10.1016/j.bja.2020.04.078
    [24] Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)[J]. JAMA Cardiol, 2020, 5:811-818. doi:  10.1001/jamacardio.2020.1017
    [25] Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China[J]. JAMA Cardiol, 2020, 5:802-810. doi:  10.1001/jamacardio.2020.0950
    [26] Ghoneim S, Butt MU, Hamid O, et al. The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population-based study[J]. Metabol Open, 2020, 8: 100057. doi:  10.1016/j.metop.2020.100057
    [27] Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK[J]. Atherosclerosis, 2020, 313: 126-136. doi:  10.1016/j.atherosclerosis.2020.09.008
    [28] Fernández García L, Puentes Gutiérrez AB, García Bascones M. Relationship between obesity, diabetes and ICU admis-sion in COVID-19 patients[J]. Med Clin (Engl Ed), 2020, 155: 314-315. doi:  10.1016/j.medcle.2020.06.008
    [29] Ochoa JB, Cárdenas D, Goiburu ME, et al. Lessons Learned in Nutrition Therapy in Patients With Severe COVID-19[J]. JPEN J Parenter Enteral Nutr, 2020, 44:1369-1375. doi:  10.1002/jpen.2005
    [30] Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study[J]. Intensive Care Med, 2020, 46: 1089-1098. doi:  10.1007/s00134-020-06062-x
    [31] Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report[J]. Chest, 2020, 158: 1143-1163. doi:  10.1016/j.chest.2020.05.559
    [32] Mauvais-Jarvis F. Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19[J]. Diabetes, 2020, 69: 1857-1863. doi:  10.2337/dbi19-0023
    [33] Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19[J]. Lancet Diabetes Endocrinol, 2020, 8: 546-550. doi:  10.1016/S2213-8587(20)30152-2
    [34] Roche provides an update on the phase Ⅲ COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia[EB/OL].(2020-07-29). https://www.roche.com/investors/updates/inv-update-2020-07-29.htm.
    [35] Huang JF, Wang XB, Zheng KI, et al. Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19[J]. Metabolism, 2020, 108: 154249. doi:  10.1016/j.metabol.2020.154249
    [36] Singer P, Blaser AR, Berger MM, et al. ESPEN guideline on clinical nutrition in the intensive care unit[J]. Clin Nutr, 2019, 38: 48-79. doi:  10.1016/j.clnu.2018.08.037
    [37] Wijaya I, Andhika R, Huang I. Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?[J]. Diabetes Metab Syndr, 2020, 14: 1241-1242. doi:  10.1016/j.dsx.2020.07.015
    [38] Susen S, Tacquard CA, Godon A, et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring[J]. Critical Care, 2020, 24: 364. doi:  10.1186/s13054-020-03000-7
    [39] Marini JJ, Gattinoni L. Management of COVID-19 Respira-tory Distress[J]. JAMA, 2020, 323: 2329-2330. doi:  10.1001/jama.2020.6825
    [40] De Jong A, Wrigge H, Hedenstierna G, et al. How to ventilate obese patients in the ICU[J]. Intensive Care Med, 2020, 46: 2423-2435. doi:  10.1007/s00134-020-06286-x
    [41] Lemyze M, Courageux N, Maladobry T, et al. Implications of Obesity for the Management of Severe Coronavirus Disease 2019 Pneumonia[J]. Crit Care Med, 2020, 48: e761-e767. doi:  10.1097/CCM.0000000000004455
    [42] Moriconi D, Masi S, Rebelos E, et al. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding[J]. Obes Res Clin Pract, 2020, 14: 205-209. doi:  10.1016/j.orcp.2020.05.009
    [43] Katulanda P, Dissanayake HA, Ranathunga I, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature[J]. Diabetologia, 2020, 63: 1440-1452. doi:  10.1007/s00125-020-05164-x
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  601
  • HTML全文浏览量:  146
  • PDF下载量:  44
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-03
  • 录用日期:  2020-11-12
  • 刊出日期:  2021-01-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！